Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q3B8N2
UPID:
LEG9B_HUMAN
Alternative names:
Galectin-9-like protein A
Alternative UPACC:
Q3B8N2; A6NLF8; A8K2J8
Background:
Galectin-9B, also known as Galectin-9-like protein A, is a protein that plays a crucial role in cellular processes by binding galactosides. This interaction is fundamental in various biological functions, including cell-cell adhesion, immune response modulation, and the regulation of cell growth and death.
Therapeutic significance:
Understanding the role of Galectin-9B could open doors to potential therapeutic strategies. Its ability to bind galactosides suggests its involvement in critical pathways that could be targeted in diseases where these processes are dysregulated.